Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends
Discover trends, market shifts, and competitive outlooks for the chemotherapy-induced nausea and vomiting (cinv) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What is the Projected CAGR for the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size from 2025 to 2034?
The market size for chemotherapy-induced nausea and vomiting (CINV) has seen robust growth in recent times. This market is projected to expand from $2.92 billion in 2024 to $3.15 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.9%. Factors contributing to the growth during the historic period include an increase in chemotherapy usage, enhanced antiemetic agents, emerging clinical guidelines, and patient advocacy.
The market for Chemotherapy-Induced Nausea and Vomiting (CINV) is predicted to experience robust expansion in the forthcoming years, reaching a valuation of $4.2 billion in 2029 at a Compound Annual Growth Rate (CAGR) of 7.5%. This development anticipated over the forecast period can be credited to personalized therapeutic approaches, advancements in antiemetic drugs, telehealth and remote supervision, and health equality efforts. Key trends expected during the forecast timeline comprise combined antiemetic treatments, ancillary care amenities, digital health mechanisms, and convalescent care.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
The surge in cancer cases is projected to stimulate the expansion of the chemotherapy-induced nausea and vomiting (CINV) market in the future. Cancer arises from a disordered multiplication and proliferation of body cells that infiltrate and damage other organs. With the growing incidences of cancer, there is an incremental urge to devise efficient and specific anti-emetic treatments to mitigate CINV, an undesirable consequence of chemotherapy. This increased interest in CINV control has guided progress in comprehending its fundamental causes and formulating new treatments. For example, the American Cancer Society (ACS), a US-based voluntary health body dedicated to abolishing cancer, anticipated in January 2023 that the country would witness around 1.9 million fresh cancer cases (about 5,370 instances daily) and approximately 609,820 cancer-related fatalities (roughly 1,670 deaths daily) in the year 2023. Thus, with the escalating prevalence of cancer, the chemotherapy-induced nausea and vomiting (CINV) market is expected to flourish. A noteworthy surge in the chemotherapy-induced nausea and vomiting (CINV) market is anticipated, driven by the escalating favorable regulatory initiatives. These initiatives define actions undertaken by regulating authorities to institute, execute, or impose regulations. These regulatory efforts can help enhance the CINV prevention and control and facilitate the formulation and application of guidelines for CINV. In one instance, the Food and Drug Administration, a US federal agency entrusted with public health protection, mentioned in October 2024 that in 2023, CDER (Center for Drug Evaluation and Research, a part of the U.S. Food and Drug Administration) sanctioned 55 unique drugs for chemotherapy-induced nausea and vomiting (CINV). Hence, the growing favorable regulatory initiatives are propelling the chemotherapy-induced nausea and vomiting (CINV) market’s expansion.
Which Segments in the Chemotherapy-Induced Nausea and Vomiting (CINV) Offer the Most Growth?
The chemotherapy-induced nausea and vomiting (CINV) market covered in this report is segmented –
1) By Form: Injectables, Oral, Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores
5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications
Subsegments:
1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections
2) By Oral: Tablets, Capsules, Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp
What Are the Fastest-Growing Geographies in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Current Market Growth and Trends in the Chemotherapy-Induced Nausea and Vomiting (CINV) Industry?
Leading businesses in the chemotherapy-induced nausea and vomiting (CINV) market are focusing on the development of unique products like a fixed intravenous antiemetic to establish a competitive edge. This refers to a set dosing of medicine delivered via IV to alleviate or prevent queasiness and vomiting, typically post-surgery or during chemotherapy. For instance, in January 2023, Glenmark Pharmaceuticals Limited, a pharmaceuticals, generics and over-the-counter (OTC) products production company based in India, launched AKYNZEO I.V. in India; this marked the country’s first-ever fixed intravenous antiemetic combo created to tackle chemotherapy-induced nausea and vomiting (CINV). The product merges netupitant and palonosetron and targets both the early and delayed stages of nausea and vomiting. The product offers convenience of a single dose, increases the complete response rates and enhances the life quality of cancer patients. Evidence from clinical studies suggest that patients undergoing highly emetogenic chemotherapy find it particularly advantageous.
View the full report here:
What Are the Key Elements That Define the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Chemotherapy-induced nausea and vomiting (CINV) is a condition that causes nausea and vomiting sensation, which can develop due to chemotherapy treatment. It is a prevalent side-effect affecting many cancer patients, affecting their quality of life and treatment results. CINV can be managed and treated through medications and lifestyle changes.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
